PRFXPAINREFORM LTD.

Nasdaq painreform.com


$ 0.92 $ -0.11 (-10.38 %)    

Wednesday, 11-Sep-2024 15:59:50 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 0.95
$ 0.91 x 200
-- x --
-- - --
$ 0.82 - $ 27.60
4,083,884
na
273,655
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 painreform-shares-are-trading-lower-today-whats-going-on

PainReform Ltd. (NASDAQ: PRFX) experienced a decline Tuesday following the company's announcement of a warrant exercise. Th...

 painreform-13d-filing-shows-lia-pure-capital-ltd-1-reported-a-720-stake-in-the-co-as-of-august-22-2024

- SEC Filing

 painreform-confirms-optimal-delivery-method-for-prf-110-in-bunionectomy-procedures-study

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110's Competitive Edge Over ...

 painreform-announces-development-and-manufacturing-of-new-formulations-providing-anti-inflammatory-and-extended-analgesic-effects

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

 painreform-announces-prf-110-promoted-normal-wound-healing-and-prevented-scar-formation-following-surgical-procedures-on-track-to-report-top-line-results-from-the-phase-3-trial-in-the-second-half-of-2024

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on tra...

 painreforms-new-manufacturing-process-achieves-18-month-stability-of-prf-110-at-room-temperature

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

 on-june-24-painreform-ilan-hadar-ceo--cfo-ceased-his-service-to-co-appointed-ehud-geller-as-interim-ceo--cfo

- SEC Filing

 maxim-group-reiterates-buy-on-painreform-maintains-2-price-target

Maxim Group analyst Naz Rahman reiterates PainReform (NASDAQ:PRFX) with a Buy and maintains $2 price target.

 painreform-completes-enrollment-in-second-part-of-its-phase-3-bunionectomy-trial-for-prf-110

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical compan...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION